Provectus Biopharmaceuticals Inc (PVCT)

[laxerpro22]

"Rumor has indicated that it might have been possible to close a Chinese license deal in the short term, but that doing it before the FDA awarded Breakthrough Therapy Designation (BTD) to PV-10 would be less lucrative. The most important implication of this is not that Provectus may get more money. In fact, for shareholders, the amount of money a Chinese company pays up-front is likely of little or no importance. More on that, later.

The important take-away from this development is that Provectus Management seems supremely confident that they will be awarded BTD status for PV-10. Surely, the price to be paid for licensing would be greater after a BTD award and lower if the BTD application is rejected... even lower than if a deal had been made before the ruling."

Agrossfarms best comment in that post today

http://www.trustintelligence.com/forum/viewtopic.php?id=1929&p=7